Abdominal aortic aneurysm (AAA) is a ballooning of the aorta, the largest blood vessel in the human body, which extends into the abdomen. If the wall of this blood vessel becomes weakened, it can stretch, "balloon" out and rupture. A rupture, if left untreated, can lead to life-threatening internal bleeding. The exact cause of this condition is unknown. However, it often occurs in older adults, especially males, those with a high cholesterol level, and in smokers. There also tends to be a genetic link to this disorder.
Consumers who queue up for health screenings at the mall, a senior center, a drug store or other retail business could benefit from the information they learn.
In recent years, the concept of multimodality imaging has emerged coincident with advances in the newer technologies of Cardiac Magnetic Resonance (CMR) and Coronary Computed Tomography (CCT).
Each year, 10,000 Americans suffer a sudden tear in the lining of their body's largest blood vessel, the aorta.
Rheumatoid arthritis, lupus, and other inflammatory rheumatic diseases are associated with a high rate of death from heart disease.
Between 5% and 10% of men aged 65 to 79 have abdominal aortic aneurysms, but don’t know it.
Regular ultrasound screening for abdominal aortic aneurysms can sharply reduce the likelihood of dying from a ruptured aneurysm among men age 65 and older, according to a new review of recent studies.
Surgery is the only treatment for an abdominal aortic aneurysm, a weak spot in the body's main artery that dilates dangerously over time.
World Congress of Cardiology Report - Acute aortic syndromes, such as large thoracic and abdominal aortic aneurysms with impending rupture, complicated acute type B dissections, traumatic rupture of thoracic aorta, still represent life-threatening conditions.
At least three severe, potentially fatal genetic diseases leave patients with aortas so flimsy that they can rupture in pregnancy and labor or even lesser activities, often without warning.
A commonly prescribed blood pressure medication may provide the first ray of hope in preventing potentially deadly complications of Marfan syndrome, a genetic disease that weakens the structural meshwork of blood vessels.
Tens of thousands of Americans live with a ticking time bomb in their chests. Now, a new University of Michigan study demonstrates that many of them may not need surgery in order to defuse it.
Patients checking into a hospital rated in the top five percent in the country have, on average, a 27 percent lower chance of mortality and a 14 percent lower risk of complications, according to a study released today by HealthGrades, the leading independent healthcare ratings company.
The screening is essential for diabetics in order to prevent amputation, heart attack and stroke, because one-third have PAD, but most do not present classic symptoms.
A team of James Cook University researchers have received more than $1 million in funding to investigate an important medical problem.
Finding biological markers that flag aneurysm, a bulging of the aorta that leads to dissection, a lengthwise separation of tissues in the artery wall, is critically important for early diagnosis.
Each year, 200,000 Americans find out that the largest blood vessel in their body, the aorta, may burst open at any time. About 20,000 die suddenly from such a rupture. And another 36,000 have surgery to repair or replace the swelling section of aorta before time runs out.
Aortic disease kills nearly 15,000 people in the United States each year, but the rarity and complexity of this deadly disorder make accurately diagnosing it difficult for doctors in the health-care trenches, University of Florida researchers have found.
Men have a four times greater risk than women of developing abdominal aortic aneurysms, estimated to be the cause of death in 4 percent of people over the age of 65, but the mechanism for this higher incidence has remained unknown.
Physicians have long been puzzled by a condition called intracranial arterial dolichoectasia, in which the larger arteries of the brain become elongated and misshapen.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.